ZA200606229B - A pharmaceutical composition - Google Patents

A pharmaceutical composition

Info

Publication number
ZA200606229B
ZA200606229B ZA200606229A ZA200606229A ZA200606229B ZA 200606229 B ZA200606229 B ZA 200606229B ZA 200606229 A ZA200606229 A ZA 200606229A ZA 200606229 A ZA200606229 A ZA 200606229A ZA 200606229 B ZA200606229 B ZA 200606229B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
ZA200606229A
Other languages
English (en)
Inventor
Jean-Pierre Sachetto
Roly Bufton
Thomas Buser
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32011882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200606229(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of ZA200606229B publication Critical patent/ZA200606229B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200606229A 2004-02-13 2005-02-07 A pharmaceutical composition ZA200606229B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0403247A GB0403247D0 (en) 2004-02-13 2004-02-13 A pharmaceutical composition

Publications (1)

Publication Number Publication Date
ZA200606229B true ZA200606229B (en) 2009-12-30

Family

ID=32011882

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200606229A ZA200606229B (en) 2004-02-13 2005-02-07 A pharmaceutical composition

Country Status (23)

Country Link
US (6) US7960370B2 (xx)
EP (1) EP1755565B2 (xx)
JP (3) JP5435842B2 (xx)
KR (1) KR101198458B1 (xx)
CN (1) CN1929824B (xx)
AR (1) AR047799A1 (xx)
AT (1) ATE457720T2 (xx)
AU (1) AU2005215198B2 (xx)
BR (1) BRPI0507473B8 (xx)
CA (1) CA2555064C (xx)
CY (1) CY1110030T1 (xx)
DE (1) DE602005019402D1 (xx)
DK (1) DK1755565T4 (xx)
ES (1) ES2344208T5 (xx)
GB (1) GB0403247D0 (xx)
IL (1) IL177462A (xx)
MX (1) MXPA06008352A (xx)
NO (1) NO341821B1 (xx)
PL (1) PL1755565T5 (xx)
PT (1) PT1755565E (xx)
SI (1) SI1755565T2 (xx)
WO (1) WO2005079853A2 (xx)
ZA (1) ZA200606229B (xx)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1660047E (pt) 2003-08-13 2014-02-27 Biocon Ltd Formulação de dosagem sólida de sais de ácidos gordos em micropartículas para agentes terapêuticos
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
CN102552213A (zh) * 2007-06-29 2012-07-11 武田药品工业株式会社 无缝胶囊
US9763989B2 (en) 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
MX2010001260A (es) * 2007-08-03 2010-04-07 Shaklee Corp Sistema de suplemento nutricional.
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
US20100130608A1 (en) * 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
JP6176894B2 (ja) * 2009-03-09 2017-08-09 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
US8207363B2 (en) * 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
CA2781525C (en) * 2009-10-23 2020-05-12 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
JP2011136927A (ja) * 2009-12-28 2011-07-14 Pfizer Inc ゼラチンカプセル及びカプセル皮膜成形用ゼラチン組成物
BR112012017831B8 (pt) 2010-01-19 2021-05-25 Dsm Ip Assets Bv óleo microbiano, alimento animal e biomassa compreendendo o referido óleo microbiano
US20140004186A1 (en) * 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
US9415035B2 (en) 2010-09-17 2016-08-16 Maine Natural Health Company, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
AU2012285806B2 (en) 2011-07-21 2017-09-14 Dsm Ip Assets B.V. Fatty acid compositions
WO2013040507A1 (en) * 2011-09-15 2013-03-21 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP3348262A1 (en) * 2012-01-06 2018-07-18 Omthera Pharmaceuticals Inc. Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
ES2606392T3 (es) * 2012-04-04 2017-03-23 Pronova Biopharma Norge As Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas
WO2013155430A1 (en) * 2012-04-13 2013-10-17 Banner Pharmacaps, Inc. Soft elastic capsules containing tablets and liquid or semisolid fills and methods for their manufacture
PT2659881T (pt) 2012-04-30 2018-01-29 Tillotts Pharma Ag Formulação de fármaco de libertação retardada
JP6173437B2 (ja) * 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
RS61557B1 (sr) 2012-06-29 2021-04-29 Amarin Pharmaceuticals Ie Ltd Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR102237356B1 (ko) 2013-10-29 2021-04-08 틸로츠 파마 아게 지연 방출 약물 제형
US9895332B2 (en) 2013-10-30 2018-02-20 Patheon Softgels, Inc. Enteric soft capsules comprising polyunsaturated fatty acids
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
EP3110408B1 (en) 2014-02-28 2019-01-16 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
DK3157936T3 (en) 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2015200563A1 (en) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Enhanced bioavailability of polysaturated fatty acids
WO2016032324A1 (en) * 2014-08-28 2016-03-03 Dezima Pharma B.V. PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS
CN105434393B (zh) * 2014-09-25 2019-07-09 四川国为制药有限公司 一种包含高含量ω-3多不饱和脂肪酸的软胶囊药物组合物
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
GB2571749A (en) * 2018-03-07 2019-09-11 Anabio Tech Limited A method inducing satiety in a mammal
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
CN109567180B (zh) * 2019-02-02 2022-03-22 北京振东光明药物研究院有限公司 一种可用于女性经、孕、产、乳期的营养品及其制备方法
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
KR20240080551A (ko) 2022-11-30 2024-06-07 주식회사 에이치씨바이오랩 유동화 코팅 공정을 이용한 유지(油脂) 함유 과립 코팅방법 및 이 방법으로 제조된 과립

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868661A (en) * 1954-08-04 1959-01-13 Wilson & Co Inc Sensitizing photographic gelatin
US2870062A (en) * 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
US2888661A (en) 1956-12-13 1959-05-26 Radio Frequency Lab Adapter for magnet charger
US3108995A (en) 1957-03-01 1963-10-29 Charles B Knox Gelatine Co Inc Method of modifying type a gelatin and product thereof
AU527784B2 (en) 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
JPS55154533A (en) 1979-05-18 1980-12-02 Kawasaki Steel Corp Stacking method for starting material such as ore
JPS5735512A (en) 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS609011B2 (ja) 1981-10-09 1985-03-07 富士カプセル株式会社 軟カプセル皮膜
EP0100052A1 (en) * 1982-07-19 1984-02-08 Syntex (U.S.A.) Inc. PGE type compositions encapsulated by acid isolated gelatin
JPS5939834A (ja) 1982-08-31 1984-03-05 Morishita Jintan Kk 製剤用皮膜組成物
DE3438291A1 (de) * 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
DE3678643D1 (de) 1985-08-16 1991-05-16 Procter & Gamble Partikel mit konstanter wirkstofffreisetzung.
SE8505569D0 (sv) 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
JPS62201823A (ja) 1986-02-28 1987-09-05 Freunt Ind Co Ltd 腸内有用細菌含有物およびその製造方法
DE3615710A1 (de) * 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
EP0289204B1 (en) * 1987-04-27 1991-07-17 Efamol Holdings Plc Lithium salt-containing pharmaceutical compositions
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8719988D0 (en) 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
JPH0774150B2 (ja) * 1987-07-31 1995-08-09 新田ゼラチン株式会社 肝油用ソフトカプセル
US4895725A (en) 1987-08-24 1990-01-23 Clinical Technologies Associates, Inc. Microencapsulation of fish oil
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
PT93637A (pt) 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
US5292522A (en) * 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
JP2836206B2 (ja) 1990-07-02 1998-12-14 味の素株式会社 炎症性腸疾患用油脂組成物
WO1992001457A1 (en) * 1990-07-20 1992-02-06 Slagel, David Products and processes for the treatment of the alimentary canal
GEP19971086B (en) 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
WO1993021912A1 (de) 1992-04-28 1993-11-11 Fresenius Ag Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
JP3895782B2 (ja) 1992-10-26 2007-03-22 生化学工業株式会社 コンドロイチナーゼ組成物およびそれを含有する注射用製剤
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
ATE173616T1 (de) * 1992-11-30 1998-12-15 Pfizer Verabreichungsvorrichtungen mit gestützten flüssigen membranen
JPH0741421A (ja) * 1993-05-28 1995-02-10 Suntory Ltd ロイコトリエンｂ４ （ｌｔｂ４ ）による医学的症状の予防及び改善剤
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
DE4422938A1 (de) 1993-06-30 1995-01-12 Siegfried Ag Pharma Neue Weichgelatinekapseln
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH11106333A (ja) * 1997-09-30 1999-04-20 Kuraray Co Ltd 脂溶性ビタミンおよび／またはカロチノイドを含有する粉末の製造法
DE19830375A1 (de) * 1998-07-08 2000-01-13 K D Pharma Bexbach Gmbh Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
EP1221947B1 (en) * 1999-10-01 2004-12-08 Natco Pharma Limited Soft gel capsule resistant to gastric juices
US6555316B1 (en) * 1999-10-12 2003-04-29 Genset S.A. Schizophrenia associated gene, proteins and biallelic markers
WO2001034646A2 (en) 1999-11-12 2001-05-17 Fibrogen, Inc. Recombinant gelatins
JP2001335481A (ja) 2000-03-22 2001-12-04 Eisai Co Ltd 高濃度ビタミンｅ含有ソフトカプセル
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030161872A1 (en) * 2002-01-04 2003-08-28 Gan-Lin Chen Capsule for holding liquid-containing compositions and method for making the same
US6663900B2 (en) * 2002-02-01 2003-12-16 Kemin Foods, Lc Microcapsules having high carotenoid content
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
ITMI20020731A1 (it) 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
GB2388776B (en) 2002-05-21 2004-08-25 Croda Int Plc Succinylated fish gelatin for use as a blood plasma expander
EP1549299B1 (en) 2002-06-05 2014-08-20 IVAX Pharmaceuticals s.r.o. Reduction of gelatin cross-linking
AU2004229165A1 (en) 2003-04-17 2004-10-28 Pharmaton S.A. Multi-vitamin and mineral supplement for pregnant women
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use

Also Published As

Publication number Publication date
WO2005079853A3 (en) 2006-01-12
KR101198458B1 (ko) 2012-11-06
US20150238430A1 (en) 2015-08-27
US9132112B2 (en) 2015-09-15
WO2005079853A2 (en) 2005-09-01
CA2555064C (en) 2011-07-05
EP1755565A2 (en) 2007-02-28
US20110097394A1 (en) 2011-04-28
US20170056354A1 (en) 2017-03-02
US9012501B2 (en) 2015-04-21
DE602005019402D1 (de) 2010-04-01
JP2012149073A (ja) 2012-08-09
SI1755565T1 (sl) 2010-08-31
CA2555064A1 (en) 2005-09-01
ES2344208T5 (es) 2018-05-17
AR047799A1 (es) 2006-02-22
ATE457720T2 (de) 2010-03-15
PL1755565T3 (pl) 2010-09-30
US20130123362A1 (en) 2013-05-16
EP1755565B2 (en) 2018-02-07
CN1929824B (zh) 2011-03-23
GB0403247D0 (en) 2004-03-17
PL1755565T5 (pl) 2018-06-29
EP1755565B1 (en) 2010-02-17
AU2005215198A1 (en) 2005-09-01
AU2005215198B2 (en) 2010-01-14
DK1755565T4 (en) 2018-05-22
SI1755565T2 (en) 2018-04-30
BRPI0507473A (pt) 2007-07-10
MXPA06008352A (es) 2007-05-23
CY1110030T1 (el) 2015-01-14
JP2007522192A (ja) 2007-08-09
US20070269507A1 (en) 2007-11-22
BRPI0507473B8 (pt) 2021-05-25
ES2344208T3 (es) 2010-08-20
NO341821B1 (no) 2018-01-29
BRPI0507473B1 (pt) 2018-06-19
US8383678B2 (en) 2013-02-26
JP5435842B2 (ja) 2014-03-05
NO20064146L (no) 2006-11-10
CN1929824A (zh) 2007-03-14
US20140228437A1 (en) 2014-08-14
JP2014139216A (ja) 2014-07-31
KR20070011307A (ko) 2007-01-24
PT1755565E (pt) 2010-04-26
IL177462A (en) 2015-09-24
DK1755565T3 (da) 2010-05-03
US7960370B2 (en) 2011-06-14
IL177462A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
ZA200606229B (en) A pharmaceutical composition
IL177480A0 (en) Pharmaceutical composition
ZA200802947B (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
IL182614A0 (en) Pharmaceutical compounds
EP1765283A4 (en) PHARMACEUTICAL COMPOSITIONS
IL182703A0 (en) Pharmaceutical compositions comprising a camtothecin derivative
IL181229A0 (en) Noncardiotoxic pharmaceutical compounds
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA200700511B (en) A pharmaceutical composition comprising gabapentin
HU0401177D0 (en) Pharmaceutical composition
GB2411355B (en) Pharmaceutical composition
GB0400452D0 (en) A pharmaceutical composition
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
ZA200701931B (en) Pharmaceutical composition
GB0409898D0 (en) A composition
EP1747205A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0428554D0 (en) Pharmaceutical compounds
GB0424742D0 (en) Pharmaceutical compounds
GB0400971D0 (en) Pharmaceutical compositions
GB0407351D0 (en) Pharmaceutical compositions
GB0402799D0 (en) Pharmaceutical composition
GB0425256D0 (en) Pharmaceutical composition
GB0425259D0 (en) Pharmaceutical composition
GB0416373D0 (en) Pharmaceutical compounds